Roche’s $50B US investment to include upcoming Boston CVRM site
Roche has pledged to upgrade three R&D sites and pointed to the recent announcement of a new home for its cardiovascular, renal and metabolism R&D work as proof that the Swiss pharma is investing serious money in the U.S. With the industry bracing for the looming threat of pharmaceutical tariffs, Roche has become the latest Big Pharma to announce a ramp-up in investment in its U.S. footprint. In an April 22 release, the Basel, Switzerland-based company said it would spend $50 billion over five years in the country, although not...